Interpretation of genotypic HIV-1 resistance to darunavir and virological response

Validation of available systems and of a new score

Andrea De Luca, Simona Di Giambenedetto, Renato Maserati, Nicola Gianotti, Pasquale Narciso, Andrea Antinori, Giovanni Di Perri, Mattia C F Prosperi, Fausto Baldanti, Valeria Micheli, Maurizio Zazzi, Carlo F. Perno, Maria M. Santoro

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: There is not yet consensus on interpretation of genotypic HIV-1 resistance to darunavir (DRV). We validated existing rules and a newly derived score. Methods: Protease inhibitor (PI)-failing patients starting a DRV/ritonavir-based regimen, with available baseline resistance genotypes, were extracted from three Italian databases. Virological response (VR) was analysed between 4 and 32 follow-up weeks, defined as a drop from baseline HIV RNA of ≥2 log10 or a value 12 weeks of follow-up. DRV/ritonavir resistance was interpreted by seven algorithms. A new weighted score (DRV-2009) was derived and validated, analysing associations of protease mutations with VR. Results: A total of 217 patients were analysed, with a mean (±sd) follow-up time of 17 (±9) weeks. At baseline, median HIV RNA was 4.26 log10 copies/ml (IQR 3.11-5.03); VR was achieved in 135/217 (62%) patients. Adjusting for use of a new drug class, number of previous PIs experienced, CD4+ T-cell count and HIV RNA, only the Rega DRV/ritonavir interpretation was significantly associated with VR (per increase in susceptibility category, OR 1.94, 95% CI 1.32-2.86; P

Original languageEnglish
Pages (from-to)489-497
Number of pages9
JournalAntiviral Therapy
Volume16
Issue number4
DOIs
Publication statusPublished - 2011

Fingerprint

HIV-1
Ritonavir
RNA
HIV
HIV-2
CD4 Lymphocyte Count
Protease Inhibitors
Peptide Hydrolases
Genotype
Darunavir
Databases
T-Lymphocytes
Mutation
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Interpretation of genotypic HIV-1 resistance to darunavir and virological response : Validation of available systems and of a new score. / De Luca, Andrea; Di Giambenedetto, Simona; Maserati, Renato; Gianotti, Nicola; Narciso, Pasquale; Antinori, Andrea; Di Perri, Giovanni; Prosperi, Mattia C F; Baldanti, Fausto; Micheli, Valeria; Zazzi, Maurizio; Perno, Carlo F.; Santoro, Maria M.

In: Antiviral Therapy, Vol. 16, No. 4, 2011, p. 489-497.

Research output: Contribution to journalArticle

De Luca, Andrea ; Di Giambenedetto, Simona ; Maserati, Renato ; Gianotti, Nicola ; Narciso, Pasquale ; Antinori, Andrea ; Di Perri, Giovanni ; Prosperi, Mattia C F ; Baldanti, Fausto ; Micheli, Valeria ; Zazzi, Maurizio ; Perno, Carlo F. ; Santoro, Maria M. / Interpretation of genotypic HIV-1 resistance to darunavir and virological response : Validation of available systems and of a new score. In: Antiviral Therapy. 2011 ; Vol. 16, No. 4. pp. 489-497.
@article{2a504fd395104bb29a2bc9a35248a2ce,
title = "Interpretation of genotypic HIV-1 resistance to darunavir and virological response: Validation of available systems and of a new score",
abstract = "Background: There is not yet consensus on interpretation of genotypic HIV-1 resistance to darunavir (DRV). We validated existing rules and a newly derived score. Methods: Protease inhibitor (PI)-failing patients starting a DRV/ritonavir-based regimen, with available baseline resistance genotypes, were extracted from three Italian databases. Virological response (VR) was analysed between 4 and 32 follow-up weeks, defined as a drop from baseline HIV RNA of ≥2 log10 or a value 12 weeks of follow-up. DRV/ritonavir resistance was interpreted by seven algorithms. A new weighted score (DRV-2009) was derived and validated, analysing associations of protease mutations with VR. Results: A total of 217 patients were analysed, with a mean (±sd) follow-up time of 17 (±9) weeks. At baseline, median HIV RNA was 4.26 log10 copies/ml (IQR 3.11-5.03); VR was achieved in 135/217 (62{\%}) patients. Adjusting for use of a new drug class, number of previous PIs experienced, CD4+ T-cell count and HIV RNA, only the Rega DRV/ritonavir interpretation was significantly associated with VR (per increase in susceptibility category, OR 1.94, 95{\%} CI 1.32-2.86; P",
author = "{De Luca}, Andrea and {Di Giambenedetto}, Simona and Renato Maserati and Nicola Gianotti and Pasquale Narciso and Andrea Antinori and {Di Perri}, Giovanni and Prosperi, {Mattia C F} and Fausto Baldanti and Valeria Micheli and Maurizio Zazzi and Perno, {Carlo F.} and Santoro, {Maria M.}",
year = "2011",
doi = "10.3851/IMP1799",
language = "English",
volume = "16",
pages = "489--497",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "4",

}

TY - JOUR

T1 - Interpretation of genotypic HIV-1 resistance to darunavir and virological response

T2 - Validation of available systems and of a new score

AU - De Luca, Andrea

AU - Di Giambenedetto, Simona

AU - Maserati, Renato

AU - Gianotti, Nicola

AU - Narciso, Pasquale

AU - Antinori, Andrea

AU - Di Perri, Giovanni

AU - Prosperi, Mattia C F

AU - Baldanti, Fausto

AU - Micheli, Valeria

AU - Zazzi, Maurizio

AU - Perno, Carlo F.

AU - Santoro, Maria M.

PY - 2011

Y1 - 2011

N2 - Background: There is not yet consensus on interpretation of genotypic HIV-1 resistance to darunavir (DRV). We validated existing rules and a newly derived score. Methods: Protease inhibitor (PI)-failing patients starting a DRV/ritonavir-based regimen, with available baseline resistance genotypes, were extracted from three Italian databases. Virological response (VR) was analysed between 4 and 32 follow-up weeks, defined as a drop from baseline HIV RNA of ≥2 log10 or a value 12 weeks of follow-up. DRV/ritonavir resistance was interpreted by seven algorithms. A new weighted score (DRV-2009) was derived and validated, analysing associations of protease mutations with VR. Results: A total of 217 patients were analysed, with a mean (±sd) follow-up time of 17 (±9) weeks. At baseline, median HIV RNA was 4.26 log10 copies/ml (IQR 3.11-5.03); VR was achieved in 135/217 (62%) patients. Adjusting for use of a new drug class, number of previous PIs experienced, CD4+ T-cell count and HIV RNA, only the Rega DRV/ritonavir interpretation was significantly associated with VR (per increase in susceptibility category, OR 1.94, 95% CI 1.32-2.86; P

AB - Background: There is not yet consensus on interpretation of genotypic HIV-1 resistance to darunavir (DRV). We validated existing rules and a newly derived score. Methods: Protease inhibitor (PI)-failing patients starting a DRV/ritonavir-based regimen, with available baseline resistance genotypes, were extracted from three Italian databases. Virological response (VR) was analysed between 4 and 32 follow-up weeks, defined as a drop from baseline HIV RNA of ≥2 log10 or a value 12 weeks of follow-up. DRV/ritonavir resistance was interpreted by seven algorithms. A new weighted score (DRV-2009) was derived and validated, analysing associations of protease mutations with VR. Results: A total of 217 patients were analysed, with a mean (±sd) follow-up time of 17 (±9) weeks. At baseline, median HIV RNA was 4.26 log10 copies/ml (IQR 3.11-5.03); VR was achieved in 135/217 (62%) patients. Adjusting for use of a new drug class, number of previous PIs experienced, CD4+ T-cell count and HIV RNA, only the Rega DRV/ritonavir interpretation was significantly associated with VR (per increase in susceptibility category, OR 1.94, 95% CI 1.32-2.86; P

UR - http://www.scopus.com/inward/record.url?scp=79959571411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959571411&partnerID=8YFLogxK

U2 - 10.3851/IMP1799

DO - 10.3851/IMP1799

M3 - Article

VL - 16

SP - 489

EP - 497

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 4

ER -